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Induction of Labor with Oxytocin: When Should Oxytocin Be Held?
Liany C. Diven, MD1; Julia Gogle, RN1; Meredith L. Rochon, MD2; Sherrine Eid, MPH3, John C. Smulian, MD, MPH2; Joanne N. Quiñones, MD, MSCE2
Abstract: 
Objective:  To determine whether there is an increase in the cesarean delivery rate and 
labor length in women undergoing induction when oxytocin is discontinued in the active 
phase of labor. 
STUDY DESIGN:  Prospective randomized controlled trial of women undergoing 
induction of labor with a term singleton gestation during February 2009-August 2011. 
Women were randomized to either oxytocin as routinely used (ROUTINE) or oxytocin 
discontinuation (DC or DISCONTINUATION) once in active labor. Induction method and 
labor management were otherwise left at the discretion of the obstetrician. Analysis was by 
intention to treat.
RESULTS:  252 patients were eligible for study analysis: 128 patients randomized to 
ROUTINE and 124 patients randomized to DC once active labor was reached. Cesarean 
delivery (CD) rate was similar between the groups (ROUTINE 25.0% [n=32] vs. DC 19.4% 
[n=24], p=0.28). There was a higher chorioamnionitis rate (ROUTINE 5.5% [n=7] vs. DC 
12.9% [n=16], p=0.04) and slightly longer active phase in those randomized to DC. In 
adjusted analysis, the rate of chorioamnionitis was not different by randomization arm but 
was explained by a longer active phase of labor [AOR 1.27 (95% CI 1.10, 1.47), p=0.001].
CONCLUSION:  Discontinuation of oxytocin once active labor is reached may 
decrease receptor desensitization without significantly increasing the CD rate, but longer 
labor duration is associated with an increased risk of chorioamnionitis.
Methods: 
Prospective randomized controlled trial of women undergoing induction with a singleton 
gestation ≥ 37 weeks at Lehigh Valley Health Network from February 2009 – August 2011. 
Women were randomized to either the ROUTINE group (oxytocin administered as an 
induction agent was continued once active labor was achieved) or the DISCONTINUATION 
group (oxytocin was discontinued once the patient was determined to be in active labor). 
Primary outcome was cesarean delivery rate between groups. Secondary outcomes 
included length of latent phase of labor, length of active phase of labor and maternal/
neonatal outcomes. Institutional review board approval was obtained. 
Induction method and labor management was otherwise at the discretion of the provider. 
Active labor was defined both by 
cervical exam (4-5 cm with regular 
contractions) and clinical assessment. 
The provider could restart oxytocin at 
any time in patients assigned to the 
DISCONTINUATION group if felt to be 
clinically indicated. 
Inclusion criteria: 
 •  Singleton gestation ≥ 37 weeks 
undergoing induction of labor with 
either misoprostol, oxytocin and 
cervical Foley balloon placement.  
Results: 
•  128 randomized to ROUTINE group, 124 to DISCONTINUATION group.  
• The most common method of induction in both groups was oxytocin.  
•  Oxytocin was restarted in the DISCONTINUATION group in 57 (47%) patients at the 
discretion of the provider. 
•  Cesarean delivery rate was similar between groups (ROUTINE 19.4% vs. 
DISCONTINUATION 25%, p=0.28). 
•  The median length of the active phase of labor (3.0 hrs vs. 3.9 hrs, p=0.02) and rates of 
chorioamnionitis (5.5% vs. 12.9%, p=0.04) were higher in the DISCONTINUATION group.  
Conclusion: 
In women undergoing induction, discontinuation of oxytocin once in active labor is not 
associated with an increased rate of cesarean delivery, but it is associated with longer labor 
duration and increased risk of chorioamnionitis. 
Exclusion criteria: 
 •  Multiple gestations 
 •  Previous cesarean delivery 
 •  Documented fetal anomalies
•  After controlling for potential confounders, oxytocin discontinuation did not increase the rate of 
cesarean delivery (AOR 0.52 [95% CI 0.14 – 1.89], p=0.32). 
•  The risk of chorioamnionitis was not increased due to discontinuation of oxytocin (AOR 1.42 [95% 
CI 0.44, 4.57], p=0.56) but was related to nulliparity (AOR 4.94 [95% CI 1.20, 20.4], p=0.03), length 
of the active phase of labor (AOR 1.27 [95% CI 1.10, 1.47], p=0.001), and the Bishop score (AOR 
0.31 [95% CI 0.10, 0.96], p=0.04). 
•  Only length of the active phase of labor was significantly associated with an increased risk of 
chorioamnionitis (AOR 1.26 [1.07, 1.47], p=0.004) when controlling for the length of the active 
phase and number of cervical exams. 















Table 4. Unadjusted analysis of potential predictors of cesarean delivery and chorioamnionitis
           Variable Cesarean delivery Chorioamnionitis
Nulliparity RR 5.91 (2.91, 12.0), p<0.001 RR 6.56 (2.0, 21.5) p<0.001
Chorioamnionitis RR 1.91 (1.08, 3.37), p=0.04 ----
Bishop score >4 RR 0.46 (0.29, 0.72), p<0.001 RR 0.36 (0.16, 0.81), p<0.001
Resident vs. Private RR 1.12 (0.70, 1.79), p=0.64 RR 0.45 (0.20, 1.02), p=0.05
Any co-morbidity RR 1.46 (0.84, 2.50), p=0.17 RR 0.63 (0.29, 1.38), p=0.25
Length of latent phase OR 1.09 (1.03, 1.16), p=0.004 OR 1.07 (1.01, 1.14), p=0.03
Length of active phase OR 1.22 (1.06, 1.40), p=0.005 OR 1.36 (1.19, 1.55), p<0.001
Number cervical exams OR 1.11 (0.99, 1.25), p=0.08 OR 1.45 (1.22, 1.73), p<0.001
Table 1. Demographic characteristics of the patient population by randomization group
           Characteristics Routine (n=128) DC (n=124) p-value
Maternal age (+SD) 27.0 + 5.6 27.7 + 5.7 0.33
Nulliparity (%) 63 (49.2) 54 (51.6) 0.70
Marital status (%)
     Married
     Divorced/widow








     Caucasian
     African American
     Latina











     Government
     Private






6 (4.8) 0.54 
Resident service [vs. private] (%) 57 (44.5) 58 (46.8) 0.72
Tobacco use (%) 17 (13.3) 18 (14.5) 0.78
Alcohol use (%) 0 (0) 1 (0.8) 0.31
Drug use (%) 0 (0) 2 (1.6) 0.15
Body mass index - kg/m2 (+SD) 31.6 + 7.3 31.0 + 7.4 0.51
Any co-morbidity (%) 88 (69.3) 81 (65.3) 0.50
Pregestational diabetes (%) 1 (0.8) 1 (0.8) 0.99
Gestational diabetes (%) 14 (10.9) 17 (13.7) 0.50
Essential hypertension (%) 5 (3.9) 6 (4.8) 0.71
Gestational hypertension or 
preeclampsia (%) 46 (35.9) 41 (33.1) 0.63
Obesity (%) [BMI > 30] 40 (31.3) 30 (24.2) 0.21
History of preterm birth (%) 3 (2.4) 7 (5.7) 0.19
Table 2. Intrapartum characteristics of the patient population by randomization group
           Characteristics Routine (n=128) DC (n=124) p-value
Gestational age at admission (weeks) 39.8 + 1.3 40.0 + 1.0 0.19
Primary indication for labor induction (%)
     Prolonged pregnancy
     Premature rupture of membranes
     Non reassuring testing
     Oligohydramnios
     Gestational hypertension or preeclampsia
     Intrauterine growth restriction
     Any diabetes
     Elective



















First method of induction (%)
     Misoprostol
     Oxytocin








     Government
     Private






6 (4.8) 0.54 
Bishop score (median) 5 (0-10) 5 (0-10) 0.82
Bishop score >4 (%) 82 (64.1) 79 (63.7) 0.95
Membrane status (%)
     Amniotomy
     Spontaneous rupture of membranes








     Epidural
     Spinal
     Local
     Intravenous sedation











Table 3. Labor and delivery characteristics by randomization group
           Cesarean delivery (%) Routine (n=128) DC (n=124) p-value
Cesarean delivery (%) 32 (25.0) 24 (19.4) 0.28
Indications for cesarean delivery (%)
     Nonreassuring fetal heart tracing
     Arrest of the active phase
     Arrest of descent
     Failed induction of labor
     Malpresentation













Oxytocin dose in active labor (mu/min) 9.8 + 5.4 10.8 + 6.3 0.25
Maximum oxytocin dose (mu/min) 13.0 + 6.8 13.1 + 6.7 0.85
Intrapartum complications
     Preeclampsia
     Chorioamnionitis
     Abruptio placentae










     Postpartum hemorrhage
     Preeclampsia diagnosed postpartum
     Endometritis









Latent phase of labor (hours)
     Mean







Active phase of labor (hours)
     Mean
     Median






Second stage of labaor (hours)
     Mean







*Other – includes conditions such as elevated blood pressures without a diagnosis of hypertension or elevated 
temperature without diagnosis of chorioamnionitis
